Machine signal
Active cluster buy — 12 distinct insiders, $523.3K, window ends Aug 20, 2026.
Active cluster sell — 4 distinct insiders, $4.2M, window ends Aug 14, 2026.
Figures computed from official regulatory filings — .
Ownershipinsiders 10.31% · institutions 42.33%
In EUR · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for SANOFI only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Market information source · Oct 5, 2026
Open-market timeline · full history
43 buys6 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| olivier Charmeil | Buy | $136.4K | conv 47Cluster |
| AMF |
| Véronique JAILLET | Buy | $4.9K | conv 55ClusterFirst in 12mo | AMF |
| Houman Ashrafian | Buy | $15.3K | conv 55ClusterFirst in 12mo | AMF |
| Thomas TRIOMPHE | Buy | $128.8K | conv 68ClusterUnusual size | AMF |
| Emmanuel FRENEHARD | Buy | $76.1K | conv 49Cluster | AMF |
| François-Xavier ROGER | Buy | $135.5K | conv 49Cluster | AMF |
| Roy PAPATHEODOROU | Sell | $1.3M | AMF |
| olivier Charmeil | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | AMF |
| olivier Charmeil | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | AMF |
| Thomas TRIOMPHE | Buy | $11.6K | conv 51Cluster | AMF |
| Thomas TRIOMPHE | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 57Cluster | AMF |
| François-Xavier ROGER | Buy | $4.8K | conv 45Cluster | AMF |
| François-Xavier ROGER | Buy | $2.4K | conv 60ClusterFirst in 12mo | AMF |
| Emmanuel FRENEHARD | Buy | $5K | conv 51Cluster | AMF |
| Audrey DUVAL | Buy | $2.4K | conv 51Cluster | AMF |
| Brendan O'CALLAGHAN | Sell | $769.7K | AMF |
| Roy PAPATHEODOROU | Sell | $73.3K | AMF |
| Natalie BICKFORD | Sell | $1.7M | AMF |
| Manuela BUXO | Sell | $368.2K | AMF |
| Audrey DUVAL | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 55ClusterFirst in 12mo | AMF |
| Brendan O'CALLAGHAN | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 61ClusterFirst in 12mo | AMF |
| olivier Charmeil | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 70ClusterFirst in 12mo | AMF |
| Manuela BUXO | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 61ClusterFirst in 12mo | AMF |
| Thomas TRIOMPHE | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 61ClusterFirst in 12mo | AMF |
| Emmanuel FRENEHARD | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 55ClusterFirst in 12mo | AMF |